Photo of Neil S. Horowitz,  MD

Neil S. Horowitz, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-8843

Neil S. Horowitz, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
  • Assistant Professor, OB/GYN, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I have a research interest in complex surgical mangement and investigating new therapeutic options for gynecologic malignancies.

I am a board certified gynecologic oncologist practicing at Brigham and Women’s Hospital and Dana Farber Cancer Institute. I finished my fellowship at Washington University, Barnes-Jewish Hospital in June of 2003 and currently an Assistant Professor within the Department of Obstetrics and Gynecology. I have been in my current position as the Director of Clinical Research within the Division of Gynecologic Oncology for 4 years. Most of my efforts are aimed at maintaining a busy clinical practice, pursuing clinical research opportunities, educating residents and fellows, and participating in national gynecologic oncology organizations.

In my role as Director of Clinical Research, I have helped develop a clinical database and tumor registry for our division. Over the last 6 months we have started to collect patient data and currently have over 300 patients in the database. As the database matures, I would anticipate this to be an important resource for fellow and resident research projects. Furthermore, I have been the Principal Investigator for 4 investigator initiated clinical trials with DFPCC and I am one of the lead accrurers to other therapeutic clinical trials. New areas of research include gestational trophblastic disease (GTD) and surgical management of epithelial ovarian cancer. I am fortunate to practice with the founders of the New England Trophoblastic Disease Center, one of the worlds leading centers for management of women with GTD. Under the mentorship of Donald P. Goldstein, MD and Ross S. Berkowitz, I have developed several ongoing research projects in this area. Additionally, I have been the Co-PI on a national ancillary data project re-evaluating the data from a large GOG trial, protocol #182. Our efforts have been aimed at better understanding the role of disease burden and surgical complexity in survival for women with ovarian cancer. Our initial data suggests primary surgery for this disease may have a limited role, thus challenging the current paradigm.

Teaching and mentoring residents and fellows is a major component of my practice. Whether it is in the operating room helping them develop into technically sound, confident and independent surgeons or in the clinic supervising them on a weekly basis, educating and mentoring residents and fellows is a major focus of my academic mission. My role on the Resident Education Committee gives me the opportunity to participate first hand in shaping the residents experience during their 4 years of training. I was fortunate to be recognized for my efforts by the residents at MGH with the Howard Ulfedder teaching award in 2006.

From a national perspective, I am an active member of the Society of Gynecologic Oncology. I am a member of the Education Committee and was chosen to be the co-chair of postgraduate education for the Program Committee 41st Annual Meeting in 2010. Additionally, I am our Society’s representative to the American College of Radiology Appropriateness Criteria Panel in which we review guidelines and recommendation for imaging in a variety gynecologic cancer settings. As a member of the Gynecologic Oncology Group, I am on both the Developmental Therapeutics and Education Committee. While on the Education Committee I was co-chair of the symposium at the January 2010 interim meeting and was asked to organize and develop the curriculum for the symposium at the July 2012 meeting. Finally, I serve on the editorial board for Gynecologic Oncology Case Reports and peer review for several journals within our field including Gynecologic Oncology, Journal of Clinical Oncology, and American Journal of Obstetricians and Gynecologists.

 

Publications

Powered by Harvard Catalyst
  • Sun SY, Melamed A, Goldstein DP, Bernstein MR, Horowitz NS, Moron AF, Maestá I, Braga A, Berkowitz RS. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: Does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol 2015; 138:46-9. PubMed
  • Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol 2015; 138:201-206. PubMed
  • Maestá I, Berkowitz RS, Goldstein DP, Bernstein MR, Ramírez LA, Horowitz NS. Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2015; 138:50-4. PubMed
  • Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol 2015. PubMed
  • Melamed A, Katz Eriksen JL, Hinchcliff EM, Worley MJ, Berkowitz RS, Horowitz NS, Muto MG, Urman RD, Feltmate CM. Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Ann Surg Oncol 2015. PubMed
  • Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer 2015. PubMed
  • Aviki EM, Esselen KM, Barcia SM, Nucci MR, Horowitz NS, Feltmate CM, Berkowitz RS, Orgill DG, Viswanathan AN, Muto MG. Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva? Gynecol Oncol 2015; 137:60-5. PubMed
  • Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL. Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182. J Clin Oncol 2015; 33:937-43. PubMed
  • Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015; 160:977-89. PubMed
  • Maestá I, Horowitz NS, Goldstein DP, Bernstein MR, Ramírez LA, Moulder J, Berkowitz RS. Response to Chemotherapy in Overweight/Obese Patients With Low-Risk Gestational Trophoblastic Neoplasia. Int J Gynecol Cancer 2015. PubMed
  • Zaino RJ, Brady WE, Todd W, Leslie K, Fischer EG, Horowitz NS, Mannel RS, Walker JL, Ivanovic M, Duska LR. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol 2014; 33:543-53. PubMed
  • Elias KM, Kang S, Liu X, Horowitz NS, Berkowitz RS, Frendl G. Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol 2014. PubMed
  • Worley MJ, Davis M, Berhie SH, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Campos SM. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol 2014; 135:54-7. PubMed
  • Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, Rose BS, Keudell AG, Wo JY. Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer 2014. PubMed
  • Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, Schorge JO, Del Carmen MG, Horowitz NS, Boruta DM. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: A SEER analysis. Gynecol Oncol 2014; 133:216-20. PubMed
  • Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, Berkowitz RS, Del Carmen MG, Schorge JO, Horowitz NS. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol 2014. PubMed
  • Davis M, Rauh-Hain JA, Andrade C, Boruta DM, Schorge JO, Horowitz NS, May T, del Carmen MG. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol 2014; 132:760-6. PubMed
  • Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol 2014; 132:55-60. PubMed
  • Mitchell DG, Javitt MC, Glanc P, Bennett GL, Brown DL, Dubinsky T, Harisinghani MG, Harris RD, Horowitz NS, Pandharipande PV, Pannu HK, Podrasky AE, Royal HD, Shipp TD, Siegel CL, Simpson L, Wong-You-Cheong JJ, Zelop CM. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol 2013; 10:822-7. PubMed
  • Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, Maxwell GL, Horowitz NS, Krivak TC. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol 2013; 130:487-92. PubMed
  • Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23:1219-25. PubMed
  • Maestá I, Growdon WB, Goldstein DP, Bernstein MR, Horowitz NS, Rudge MV, Berkowitz RS. Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 2013; 130:312-6. PubMed
  • Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, Del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol 2013; 129:63-8. PubMed
  • Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol 2013; 129:69-73. PubMed
  • Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol 2012. PubMed
  • Quick CM, May T, Horowitz NS, Nucci MR. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol 2012; 31:337-43. PubMed
  • Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol 2012. PubMed
  • Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol 2012. PubMed
  • Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS, Del Carmen MG. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol 2012. PubMed
  • Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 124:53-8. PubMed
  • Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, Del Carmen MG, Schorge JO. Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer. Ann Surg Oncol 2011. PubMed
  • Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent M端llerian Carcinoma. 2011; 4:26-33. PubMed
  • Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2009; 28:154-9. PubMed
  • Horowitz NS,Goldstein DP,Berkowitz RS. Management of gestational trophoblastic neoplasia. Semin Oncol 2009; 36:181-9. PubMed
  • Matulonis UA,Krag KJ,Krasner CN,Atkinson T,Horowitz NS,Lee H,Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol Oncol 2008; 112:394-9. PubMed
  • Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2008; 26:5761-6. PubMed
  • Growdon WB,Boisvert SL,Akhavanfard S,Oliva E,Dias-Santagata DC,Kojiro S,Horowitz NS,Iafrate AJ,Borger DR,Rueda BR. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol 2008; 111:289-97. PubMed
  • Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med 2006; 354:1615-25. PubMed
  • Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, Grigsby PW, Siegel BA, Mutch DG. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004; 95:546-51. PubMed
  • Rauh-Hain JA, Shoni M, Schorge JO, Goodman A, Horowitz NS, del Carmen MG. Prognostic determinants in patients with uterine and ovarian carcinosarcoma. J Reprod Med 2013; 58:297-304. PubMed
  • Owusu-Darko S, Rauh-Hain JA, Horowitz NS, Goodman A, Schorge JO, Del Carmen MG. Comparison of outcomes in patients with early-stage mucinous endometrial cancer and those with endometrioid endometrial cancer, with and without adjuvant therapy. J Reprod Med 2015; 59:527-33. PubMed
  • Rauh-Hain JA, Goodman A, Boruta DM, Schorge JO, Horowitz NS, del Carmen MG. Endometrial stromal sarcoma: a clinicopathologic study of 29 patients. J Reprod Med 2015; 59:547-52. PubMed
Hide